A Study to Learn About the Safety and Immune Activity of RSVpreF in Children 2 to <18 Years of Age
Public ClinicalTrials.gov record NCT05900154. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A PHASE 1, OPEN-LABEL, AGE-DESCENDING, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE (RSVpreF) IN CHILDREN 2 TO <18 YEARS OF AGE
Study identification
- NCT ID
- NCT05900154
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Pfizer
- Industry
- Enrollment
- 128 participants
Conditions and interventions
Conditions
Interventions
- RSVpreF 120 µg Biological
- RSVpreF 60 µg Biological
Biological
Eligibility (public fields only)
- Age range
- 2 Years to 17 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 21, 2023
- Primary completion
- Feb 28, 2024
- Completion
- Feb 28, 2024
- Last update posted
- Mar 5, 2025
2023 – 2024
United States locations
- U.S. sites
- 17
- U.S. states
- 13
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham - School of Medicine | Birmingham | Alabama | 35233 | — |
| Stanford University Medical Center | Palo Alto | California | 94304 | — |
| Peninsula Research Associates | Rolling Hills Estates | California | 90274 | — |
| Bio-Medical Research LLC | Miami | Florida | 33144 | — |
| Velocity Clinical Research, Sioux City | Sioux City | Iowa | 51106 | — |
| Velocity Clinical Research, New Orleans | Metairie | Louisiana | 70006 | — |
| Velocity Clinical Research, Omaha | Omaha | Nebraska | 68134 | — |
| Rochester Clinical Research, LLC | Rochester | New York | 14609 | — |
| Duke Vaccine And Trials Unit | Durham | North Carolina | 27703 | — |
| Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio | 45229 | — |
| Senders Pediatrics | South Euclid | Ohio | 44121 | — |
| Velocity Clinical Research, Providence | East Greenwich | Rhode Island | 02818 | — |
| Innovo Research - Austin Regional Clinic | Austin | Texas | 78726 | — |
| Velocity Clinical Research, Austin | Austin | Texas | 78759 | — |
| Velocity Clinical Research, Salt Lake City | West Jordan | Utah | 84088 | — |
| Seattle Children's - Building Cure | Seattle | Washington | 98101 | — |
| Seattle Children's Hospital | Seattle | Washington | 98105 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05900154, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 5, 2025 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05900154 live on ClinicalTrials.gov.